Nexlizet (Bempedoic Acid/Ezetimibe) Patent Expiration, LOE Window & CMS Spending

Nexlizet (Bempedoic Acid/Ezetimibe) by Esperion Therapeutics: FDA Orange Book core substance LOE 2040-06-19, 0 AB generics, $77.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEsperion Therapeutics
FDA Application & PathwayN211617 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-06-19
Last Listed Patent or Exclusivity Date2040-06-19
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$77.0M
2024 Medicare Part D Spend$70.8M
2024 Medicaid Spend$6.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 20.0% 2-yr change)